Results 261 to 270 of about 86,123 (283)
Some of the next articles are maybe not open access.

The new inotropic phosphodiesterase inhibitors

Archives Internationales de Physiologie et de Biochimie, 1984
Compounds with phosphodiesterase inhibitory activity stimulate myocardial contractility by increasing the intracellular cyclic AMP concentrations. They can also increase Ca2+ entry and inhibit Ca2+ sequestration by the sarcoplasmic reticulum. Xanthines produce bronchodilation with associated venous and arteriolar dilation. However, their use is limited
D, el Allaf, V, D'Orio, J, Carlier
openaire   +2 more sources

Phosphodiesterase Type 5 (PDE5) Inhibitors

2003
Publisher Summary In recent years, the field of Phosphodiesterase Type 5 (PDE5) inhibitors has reached a state of maturity. Standard issues in medicinal chemistry, such as potency, selectivity, physico-chemical properties and oral bioavailability, have been successfully addressed with the known PDE5 inhibitors.
Helmut, Haning   +2 more
openaire   +2 more sources

Phosphodiesterase Inhibitors for Cognitive Enhancement

Current Pharmaceutical Design, 2005
An effective treatment for age-related cognitive deficits remains an unmet medical need. Currently available drugs for the symptomatic treatment of Alzheimer's disease or other dementias have limited efficacy. This may be due to their action at only one of the many neurotransmitter systems involved in the complex mechanisms that underlie cognition.
Gregory M, Rose   +3 more
openaire   +2 more sources

Phosphodiesterase inhibitors in clinical urology

Expert Review of Clinical Pharmacology, 2013
To date, benign diseases of the male and female lower urinary and genital tract, such as erectile dysfunction, bladder overactivity, lower urinary tract symptomatology secondary to benign prostatic hyperplasia and symptoms of female sexual dysfunction (including arousal and orgasmic disorders), can be therapeutically approached by influencing the ...
Stefan, Ückert   +2 more
openaire   +2 more sources

Phosphodiesterase Inhibitors: History of Pharmacology

2011
The first pharmacological investigations of phosphodiesterase (PDE) inhibitors were developed with the clinical efficacies of drugs isolated from coffee, cacao and tea but only later their relevant ingredients were identified as xanthines that act as PDE.
Christian, Schudt   +3 more
openaire   +2 more sources

Phosphodiesterase inhibitors in airways disease

European Journal of Pharmacology, 2006
Phosphodiesterases hydrolyse intracellular cyclic nucleotides, cyclic adenosine monophosphate (cAMP) and cyclic guanosine monophosphate (cGMP) into inactive 5' monophosphates, and exist as 11 families. They are found in a variety of inflammatory and structural cells.
openaire   +2 more sources

Phosphodiesterase Inhibitors in Raynaud's Phenomenon

Annals of Pharmacotherapy, 2006
Objective: TO evaluate the efficacy of the phosphodiesterase type 5 (PDE5) inhibitors in the treatment of Raynaud's phenomenon. Data Sources: Searches of MEDLINE (1966–March 2006) and Web of Science (1980–March 2006) were conducted; search terms were sildenafil, tadalafil, vardenafil, phosphodiesterase, and Raynaud.
openaire   +2 more sources

Phosphodiesterase inhibitors

Baillière's Clinical Anaesthesiology, 1994
J. Boldt, G. Hempelmann
openaire   +1 more source

Phosphodiesterase Inhibitors

2010
R. Hamish McAllister-Williams   +199 more
openaire   +1 more source

Home - About - Disclaimer - Privacy